|
摘要：
|
|
摘要：代谢相关脂肪性肝病（metabolic dysfunction-associated fatty liver disease，MAFLD）
的全球患病率为20%～40%，伴随着沉重的疾病负担和晚期疾病相关的高病死率，目前
尚无批准治疗MAFLD的标准药物。法尼醇X受体（farnesoid X receptor，FXR）具有调控
糖脂代谢和改善胰岛素抵抗的作用，其中奥贝胆酸作为FXR激动剂，已被多项研究证实
可改善MAFLD患者的肝组织学特征。本文主要阐述FXR激动剂的作用机制和研究现状
以供临床参考。
|
|
Abstract: The global prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD)
is 20%～40%, and with a heavy disease burden and a high mortality rate associated with advanced
disease, there is still no approved standard drug for the treatment of MAFLD. farnesoid X receptor
(FXR) can regulate glycolipid metabolism and improve insulin resistance. Obercholic acid, as an
FXR agonist, has been confirmed to improve the hepatic histological characteristics of patients
with MAFLD in some studies. This paper described the mechanism of action of FXR agonist and
its current research status for clinical reference.
|
|
基金项目：
|
|
|
|
作者简介：
|
|
|
|
参考文献：
|
|
|
|
服务与反馈：
|
|
【文章下载】【加入收藏】
|
|
|
|